Capricor Therapeutics recently announced positive final 12-month results from the HOPE-2 Trial. HOPE-2 was a randomized, double-blind, placebo-controlled study focused on later-stage Duchenne patients. On June 3, 2020, Capricor joined PPMD for a webinar to discuss Capricor’s HOPE-2 clinical program.
If you missed the live event, the recording can be found below.
Watch the Recording